Puma Biotechnology Inc., of Los Angeles, and Specialised Therapeutics Asia Pte Ltd., of Singapore, entered an exclusive agreement under which Specialised Therapeutics will commercialize Nerlynx (neratinib) throughout Southeast Asia, beginning with Australia, Singapore, Malaysia, Brunei and New Zealand.